Bli medlem
Bli medlem

Du är här

2015-04-14

Esperite N.V.: ESPERITE (ESP) validates SERENITY, the breast and ovarian cancer risk screening test that sequences the entire BRCA1 and BRCA2 genes and detects

SERENITY, early detection of genetic predisposition to breast and ovarian
cancer, widely accessible in Europe by May's end

Geneva, Switzerland - 14 April 2015

ESPERITE
launches its oncology genetic tests with SERENITY; the risk-free, convenient,
and accurate test that screens the entire coding regions of the BRCA1 and
BRCA2 genes, detecting all variants and reporting results in less than 15
days. ESPERITE's local commercial structures will make SERENITY widely
accessible throughout Europe at an end-user price of 520 euros. The fully
validated SERENITY test has already confirmed its market potential with
oncologist, gynecologists and customers in five countries.

Sophia Genetics' bio-informatics platform ensures SERENITY top analytical
performance and the highest specificity and sensitivity in the market.
SERENITY provides the most comprehensive genetic information to ascertain the
risk of breast and ovarian cancer, and address it most effectively. Early
detection and precise identification of BRCA1 and BRCA2 variants saves lives.
SERENITY empowers clients and doctors to take preventive personalized
actions best-suited for the identified mutation, resulting in vastly improved
survival rates and better quality of life.

Genoma, proteomics and genetic predictive medicine division ofESPERITE
, primes SERENITY with the most advanced features for commercial leadership:
CE-IVD and ISO13485 certified processes, fully validated accuracy and
reliability, and compliant with the most stringent quality standards, laws
and directives in the EU and Switzerland.

SERENITY is performed in Genoma's state-of-the-art lab in Geneva, the largest
clinical genetic center in Europe, with Next Generation Sequencing (NGS)
technologies. Genoma's world-class experts with extensive experience in BRCA
analysis by NGS produce the genetic information that is interpreted by Swiss
State-certified expert onco-geneticists.

Breast cancer is the most common cancer among European women with growing
incidence rates (499,560 in 2012). The global market for breast cancer
diagnostic and drug technologies was about $20.8 billion in 2012 and is
expected to reach $27 billion in 2019. Ovarian cancer was diagnosed in
65,538 women in Europe in 2012. There is an increasing demand for genetic
testing as product awareness permeates society and larger segments move into
predictive and preventive medicine. Strong growth is benchmarked for
SERENITY, a high-profit-generating product.

BRCA1 and BRCA2 discoveries have fundamentally changed the management of
hereditary breast and ovarian cancer. BRCA1 and BRCA2 are tumor suppressor
genes that help to ensure the stability of the cell's genetic material. When
either of these genes suffers a mutation, DNA damage may not be repaired
properly, and cells are more likely to develop additional genetic alterations
resulting in cancer. Certain mutations in BRCA1 and BRCA2 genes predispose
to greatly increased risks of up to 80% for breast cancer and up to 50% for
ovarian cancer. BRCA mutations account for 5-10% of all breast cancers and
10-15% of all ovarian cancers.

About 50% of women with mutations in BRCA1 or BRCA2 have no family history of
breast or ovarian cancer and ignore they carry cancer-causing mutations. A
survey revealed that only 19% of US primary care physicians accurately
assessed family history for BRCA1 and BRCA2 testing (AmJ PrevMed.
2011;40(1):61-66). Absent population-wide screening, many women with BRCA1
or BRCA2 mutations would not be identified until they developed cancer,
because standard diagnostics only detect already present changes in the
tissue.

Leading scientists advocate for BRCA1 and BRCA2 genetic screening for every
woman at about age 30 as part of routine medical care. SERENITY will
facilitate the medical community's ongoing shift towards broader genetic
screening policies. Most types of inherited breast and ovarian cancer can be
prevented, if early detected: SERENITY makes it possible. Other genetic
tests don't screen the entire BRCA1 and BRCA2 genes and/or can only detect
certain mutations, or screen other genes which provide information with no
preventive value.

Frederic Amar, CEO ofESPERITE
group: "SERENITY materializes our commitment to improve health in society by
reducing cancer morbidity and mortality. Accessible throughout Europe at an
affordable price, SERENITY reflects as well our commercial strategy and
competitive advantage. SERENITY is a quality milestone in preventive
medicine, and positions Genoma as a reference in the fast-growing oncology
genetic screening market."

About ESPERITE

ESPERITE
group, listed at Euronext Amsterdam and Paris, is a leading international
company in regenerative and predictive medicine since 2000, operational in
nearly 40 countries with a network of 6,000 clinics worldwide. ESPERITE
serves clients in its state-of-the-art lab facilities in Geneva coupled with
ultra-modern processing and storage facilities in Belgium, Switzerland,
Germany, Dubai, South Africa and Portugal. Its family stem cell bank,
CryoSave, stores 280,000 samples from umbilical cord blood and cord tissue.

To learn more about theESPERITE
group, or to book an interview with CEO Frederic Amar: +31 575 548 998 -
ir@esperite.com or visit the websites atwww.esperite.com andwww.genoma.com.

ESPERITE PR Serenity. Eng
http://hugin.info/143308/R/1910794/681568.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via Globenewswire

HUG#1910794

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.